Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2023 Oct 11

PMID 37818448

Authors

Kwonmok Ko

Ben Carter

Anthony J Cleare

James J Rucker

Affiliations

Soon will be listed here.

Abstract

Introduction: In psychedelic therapy, mystical as well as challenging experience may influence therapeutic outcome. However, predictors of such experience have not been sufficiently established. Determining predictors of their intensity is, therefore, potentially beneficial in targeting psilocybin therapy for depression.

Methods: In a post hoc data analysis of a Phase 1, randomised, double-blind, placebo-controlled, between-groups clinical trial, dosage, personality traits, affect, and individual data were analysed as possible clinical predictors. Eighty-nine healthy volunteers were randomised to receive a single dose of placebo, 10 mg of psilocybin, or 25 mg of psilocybin. ANOVA was used to analyse the relationship between dosage and mystical and/or challenging experience, and correlation analysis for all other variables.

Results: The intensity of both mystical and challenging experience was strongly associated with higher dosage. Age was negatively correlated with intensity of challenging experience. Correlation between identified personality traits and either mystical or challenging experience was minimal, with the exception of positive correlation between neuroticism and challenging experience at higher dose. Neither positive nor negative affect indicated correlation with the intensity of either type of experience.

Discussion: A limitation of this study is its post hoc, exploratory design; recommendations for further research are provided.

Citing Articles

The Role of the Serotonergic System in Time Perception: A Systematic Review.

Akhmirov R, Mitiureva D, Zaichenko M, Smirnov K, Sysoeva O Int J Mol Sci. 2025; 25(24.

PMID: 39769070 PMC: 11679555. DOI: 10.3390/ijms252413305.

Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience.

Nicholas C, Banks M, Lennertz R, Wenthur C, Krause B, Riedner B Transl Psychiatry. 2024; 14(1):372.

PMID: 39266503 PMC: 11393325. DOI: 10.1038/s41398-024-03059-8.

Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants.

Vizeli P, Studerus E, Holze F, Schmid Y, Dolder P, Ley L Transl Psychiatry. 2024; 14(1):357.

PMID: 39231959 PMC: 11374807. DOI: 10.1038/s41398-024-03074-9.

Effects of Psychedelics in Older Adults: A Prospective Cohort Study.

Kettner H, Roseman L, Gazzaley A, Carhart-Harris R, Pasquini L Am J Geriatr Psychiatry. 2024; 32(9):1047-1059.

PMID: 38849218 PMC: 11316630. DOI: 10.1016/j.jagp.2024.05.007.

References

Griffiths R, Johnson M, Richards W, Richards B, McCann U, Jesse R . Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011; 218(4):649-65. PMC: 3308357. DOI: 10.1007/s00213-011-2358-5. View

Smigielski L, Kometer M, Scheidegger M, Krahenmann R, Huber T, Vollenweider F . Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep. 2019; 9(1):14914. PMC: 6813317. DOI: 10.1038/s41598-019-50612-3. View

Roseman L, Nutt D, Carhart-Harris R . Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Front Pharmacol. 2018; 8:974. PMC: 5776504. DOI: 10.3389/fphar.2017.00974. View

Aday J, Davis A, Mitzkovitz C, Bloesch E, Davoli C . Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects. ACS Pharmacol Transl Sci. 2021; 4(2):424-435. PMC: 8033773. DOI: 10.1021/acsptsci.1c00014. View

Schmid Y, Liechti M . Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology (Berl). 2017; 235(2):535-545. PMC: 5813062. DOI: 10.1007/s00213-017-4733-3. View

Romeo B, Hermand M, Petillion A, Karila L, Benyamina A . Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. J Psychiatr Res. 2021; 137:273-282. DOI: 10.1016/j.jpsychires.2021.03.002. View

Griffiths R, Richards W, McCann U, Jesse R . Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006; 187(3):268-83. DOI: 10.1007/s00213-006-0457-5. View

Carhart-Harris R, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I . Psychedelics and the essential importance of context. J Psychopharmacol. 2018; 32(7):725-731. DOI: 10.1177/0269881118754710. View

Studerus E, Gamma A, Kometer M, Vollenweider F . Prediction of psilocybin response in healthy volunteers. PLoS One. 2012; 7(2):e30800. PMC: 3281871. DOI: 10.1371/journal.pone.0030800. View

10.

Goldberg L . The structure of phenotypic personality traits. Am Psychol. 1993; 48(1):26-34. DOI: 10.1037//0003-066x.48.1.26. View

11.

Goodwin G, Aaronson S, Alvarez O, Atli M, Bennett J, Croal M . Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord. 2023; 327:120-127. DOI: 10.1016/j.jad.2023.01.108. View

12.

Rucker J, Marwood L, Ajantaival R, Bird C, Eriksson H, Harrison J . The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. J Psychopharmacol. 2022; 36(1):114-125. PMC: 8801675. DOI: 10.1177/02698811211064720. View

13.

Dittrich A . The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998; 31 Suppl 2:80-4. DOI: 10.1055/s-2007-979351. View

14.

Liechti M, Dolder P, Schmid Y . Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology (Berl). 2016; 234(9-10):1499-1510. PMC: 5420386. DOI: 10.1007/s00213-016-4453-0. View

15.

Carbonaro T, Bradstreet M, Barrett F, MacLean K, Jesse R, Johnson M . Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol. 2016; 30(12):1268-1278. PMC: 5551678. DOI: 10.1177/0269881116662634. View

16.

Griffiths R, Richards W, Johnson M, McCann U, Jesse R . Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008; 22(6):621-32. PMC: 3050654. DOI: 10.1177/0269881108094300. View

17.

Griffiths R, Johnson M, Carducci M, Umbricht A, Richards W, Richards B . Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016; 30(12):1181-1197. PMC: 5367557. DOI: 10.1177/0269881116675513. View

18.

McCartney A, McGovern H, De Foe A . Predictors of Psychedelic Experience: A Thematic Analysis. J Psychoactive Drugs. 2022; 55(4):411-419. DOI: 10.1080/02791072.2022.2129885. View

19.

Garcia-Romeu A, Griffiths R, Johnson M . Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2015; 7(3):157-64. PMC: 4342293. DOI: 10.2174/1874473708666150107121331. View

20.

Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt D . Self-blinding citizen science to explore psychedelic microdosing. Elife. 2021; 10. PMC: 7925122. DOI: 10.7554/eLife.62878. View